```
 d his

     (FILE 'HOME' ENTERED AT 10:39:27 ON 04 JAN 2002)

     FILE 'REGISTRY' ENTERED AT 10:39:44 ON 04 JAN 2002
L1                STRUCTURE UPLOADED
L2             0 S L1
L3             3 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 10:41:15 ON 04 JAN 2002
               S L1

     FILE 'REGISTRY' ENTERED AT 10:41:20 ON 04 JAN 2002
L4             0 S L1

     FILE 'CAPLUS' ENTERED AT 10:41:23 ON 04 JAN 2002
L5             0 S L4

     FILE 'CAPLUS' ENTERED AT 10:41:36 ON 04 JAN 2002
L6             2 S L3
L7             2 S L6
                 SELECT L6 1 RN

     FILE 'REGISTRY' ENTERED AT 10:44:00 ON 04 JAN 2002
L8            49 S E1-49

     FILE 'BEILSTEIN' ENTERED AT 10:46:16 ON 04 JAN 2002
L9             4 S L1
L10           37 S L1 SSS FULL
L11            0 S L10 AND PY<1998

     FILE 'STNGUIDE' ENTERED AT 10:50:10 ON 04 JAN 2002

     FILE 'MARPAT' ENTERED AT 10:54:39 ON 04 JAN 2002
L12            0 S L3
L13            6 S L3 SSS FULL

     FILE 'CAPLUS' ENTERED AT 10:56:15 ON 04 JAN 2002
L14            6 S L13

=> s l14 not l6
L15           5 L14 NOT L6

=> d l1
L1 HAS NO ANSWERS
L1                STR
```



Structure attributes must be viewed using STN Express query preparation.

=> d 1-5 fbib abs

L15 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 2001:228892 CAPLUS
DN **134:266142**
TI Preparation of 7-acylamino-3-heteroarylthio-3-cephem carboxylic acid derivatives as antibiotics and prodrugs
IN Hecker, Scott J.; Cho, Aesop; Glinka, Tomasz W.; Calkins, Trevor; Lee, Ving J.
PA Microcide Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001021623	A1	20010329	WO 2000-US26069	20000921
	W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RO, RU, SG, SK, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				US 1999-155496 P	19990922

OS MARPAT 134:266142
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Antimicrobial (7R)-7-acylamino-3-heteroarylthio-3-cephem-4-carboxylic acid derivs. I and II [R = [(alk1)p(R99)q(alk2)rR12]1-2; R1 = aryl and pyridyl, thiadiazolyl or thiazolyl heterocycles substituted with OH, Br, F, Cl, I,

SH, CN, alkylthio, carboxyl, oxo, alkoxycarbonyl, alkyl, alkenyl, nitro, amino, alkoxyl and carboxamido; R2 = H, substituted alkyl, alkenyl, aryl, aralkyl or trialkylsilyl; R11 = H, halogen, OH, substituted alkyl, alkoxy, amino; alk1 and alk2 = alkylene groups; p = 0 or 1; R99 = NH, S, SO, SO2; q = 0 or 1; r = 0 or 1; R12 = NR21R22, NR23C(=NR24)NR25R26, C(=NR27)NR28R29, NR30CH(=NR31) and R21R31 are independently H and alkyl; A, B, D, L, E, G, J are independently N or C forming 3- or 4-pyridyl, 2-pyrazinyl, 4-pyrimidinyl, 2- or 5-thiazolyl-, 2-1,3,4-thiadiazolyl, 5-1,2,4-thiadiazolyl] or their pharmaceutically acceptable salts and prodrugs were prepd. These cephalosporins were evaluated for antimicrobial activity against a panel of bacterial strains and found to exhibit antibiotic activity against a wide spectrum of organisms including organisms which are resistant to methicillin-resistant bacteria or other .beta.-lactam antibiotics and are useful as antibacterial agents with the preferred dose of 2.0-250 mg/kg of the patient body wt. administered between 1-4 times/day. Thus III was prepd. in good yield starting from 2-(tert-butoxycarbonyl)aminoethylthiol and 2-bromo-4-chloromethyl-1,3-thiazole via a multistep synthesis.

RE.CNT 10
RE
(1) Blank, B; JOURNAL OF MEDICINAL CHEMISTRY 1974, V17(10), P1065 CAPLUS
(2) Ciba Geigy Ag; EP 0022245 A 1981 CAPLUS
(3) Ciba Geigy Ag; EP 0025017 A 1981 CAPLUS
(4) Kim, M; WO 9958535 A 1999 CAPLUS
(5) Merck & Co Inc; WO 9602548 A 1996 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 2000:666701 CAPLUS
DN **133:252050**
TI Preparation of novel N-cyanomethyl amide compounds and compositions as protease inhibitors to treat osteoporosis
IN Bryant, Clifford M.; Palmer, James T.; Rydzewski, Robert M.; Setti, Eduardo L.; Tian, Zong-Qiang; Venkatraman, Shankar; Wang, Dan-Xiong
PA Axys Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000055126	A2	20000921	WO 2000-US6837	20000315
	WO 2000055126	A3	20010222		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1999-124420 P	19990315
	EP 1161415	A2	20011212	EP 2000-916375	20000315
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				US 1999-124420 P	19990315
				WO 2000-US6837 W	20000315
	NO 2001004484	A	20011026	NO 2001-4484	20010914

US 1999-124420 P 19990315
WO 2000-US6837 W 20000315

PATENT FAMILY INFORMATION:

FAN 2000:666700

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000055125	A2	20000921	WO 2000-US6747	20000315
	WO 2000055125	A3	20010426		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 1999-124420 P 19990315

	NO 2001004485	A	20011105	NO 2001-4485	20010914

US 1999-124420 P 19990315
WO 2000-US6747 W 20000315

OS MARPAT 133:252050

AB Title compds. [R1R2NCR3R4CN; R1 = R11R7NCR5R9X1, R11R8NCR6R10X2NR7CR5R9CX1; X1, X2 independently = CO, CH2SO2; R5, R6 independently = H, C1-6alkyl; R7, R8 independently = H, C1-6alkyl; R9, R10 independently = (un)substituted-C1-6alkyl; R9-R7 = trimethylene, tetramethylene, phenylene-1,2-dimethylene; R10-R8 = trimethylene, tetramethylene, phenylene-1,2-dimethylene; R5-R9 = C3-8cycloalkylene, C3-8heterocycloalkylene; R10-R6 = C3-8cycloalkylene, C3-8heterocycloalkylene; R11 = X4X5R18; X4 = CO, COCO, SO2; X5 = bond, O, NH; R18 = C1-6alkyl; R2 = H, C1-6alkyl; R3 = H, C1-6alkyl; R4 = CN, COOH, COOC1-6alkyl; R2-R4 = trimethylene, tetramethylene, phenylene-1,2-dimethylene; R4-R3 = C3-8cycloalkylene, C3-8heterocycloalkylene], N-oxide, prodrug, isomers, pharmaceutically acceptable salts, and compn. are prepd. as therapeutically effective estrogen receptor agonist. Title compds. are claimed in treating osteoporosis in post-menopausal woman in which cathepsin K activity contributes to the pathol. and symptomatol. of the disease. Thus, the title compd. (S)-C6H5CH2OCONHCH(CH2CH(CH3)2)CONHCH2CN was prepd.

L15 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2002 ACS

AN 2000:666700 CAPLUS

DN **133:252170**

TI Preparation of novel N-cyanomethyl amides as protease inhibitors

IN Bryant, Clifford M.; Bunin, Barry A.; Kraynack, Erica A.; Patterson, John W.

PA Axys Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 137 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000055125	A2	20000921	WO 2000-US6747	20000315
	WO 2000055125	A3	20010426		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG,

SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 1999-124420 P 19990315

NO 2001004485 A 20011105 NO 2001-4485 20010914
US 1999-124420 P 19990315
WO 2000-US6747 W 20000315

PATENT FAMILY INFORMATION:

FAN 2000:666701

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000055126	A2	20000921	WO 2000-US6837	20000315
	WO 2000055126	A3	20010222		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 1999-124420 P 19990315

EP 1161415 A2 20011212 EP 2000-916375 20000315
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
US 1999-124420 P 19990315
WO 2000-US6837 W 20000315

NO 2001004484 A 20011026 NO 2001-4484 20010914
US 1999-124420 P 19990315
WO 2000-US6837 W 20000315

OS MARPAT 133:252170

GI



I



II



III



IV

AB The title compds. [I; R1 = II, III (wherein X1, X2 = CO, CH2SO2; R5, R6 = H, alkyl; R7, R8 = H, alkyl, etc.; R9, R10 = alkyl optionally substituted with CN, halo, NO2, etc.; R11 = X5X6R18; X5 = CO, COCO, SO2; X6 = a bond, O, NH, N(alkyl); R18 = alkyl optionally substituted with CN, halo, NO2, etc.); R2 = H, alkyl, etc.; R3 = H, alkyl, etc.; R4 = H, alkyl optionally

substituted with CN, halo, NO2, etc.; R4 and R2 taken together form trimethylene, tetramethylene, phenylene-1,2-dimethylene, optionally substituted with hydroxy, oxo or methylene; R4 and R3 together with the carbon atom to which both are attached form cycloalkylene, heterocycloalkylene], useful for treating diseases assocd. with cysteine protease activity, particularly diseases assocd. with activity of cathepsins B, K, L or S such as inflammation and asthma, were prepd. and formulated. Thus, reacting 2(S)-tert-butoxycarbonylamino-3-phenylpropionic acid with aminoacetonitrile.HCl in the presence of Et3N in DMF and MeCN afforded the amide (1S)-IV. Biol. data for compds. I were given.

L15 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 2000:666699 CAPLUS
DN **133:251875**
TI Preparation of esters as protease inhibitors
IN Buysse, Ann M.; Mendonca, Rohan V.; Palmer, James T.; Tian, Zong-Qiang; Venkatraman, Shankar
PA Axys Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000055124	A2	20000921	WO 2000-US7145	20000315
WO 2000055124	A3	20010816		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 1999-124529 P 19990315

EP 1159260 A1 20011205 EP 2000-918085 20000315

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

US 1999-124529 P 19990315
WO 2000-US7145 W 20000315

OS MARPAT 133:251875
AB R1X1NR2CHR3COR4 [X1 = bond or divalent group; R1 = H, X6X7R16; R2 = H, alkyl; R3 = H, optionally substituted alkyl; R2R3 = trimethylene, tetramethylene, phenylene-1,2-dimethylene; R4 = nitromethyl, 1-hydroxy-1-methylethyl, etc.], cysteine protease inhibitors, were prepd. E.g., benzyl 1S-(3-hydroxy-2-oxo-1S-phenethylpropylcarbamoyl)-3-methylbutylcarbamate was prepd. The test compds. were inhibitors of cathepsin B, K, L, and S (no data).

L15 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 1994:134290 CAPLUS
DN **120:134290**
TI Preparation of .alpha.-(sulfonylamino)-N-(4-pyridyl)benzenepropanamides and their pharmaceutical formulations as analgesics
IN Bru-Magniez, Nicole; Sartori, Eric; Teulon, Jean Marle
PA Laboratories Upsa, Fr.
SO Fr. Demande, 28 pp.

CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2683817	A1	19930521	FR 1991-14187	19911118
	FR 2683817	B1	19940225		

OS MARPAT 120:134290
GI



I

II

AB Title compds. racemic or (R)- or (S)-I [R = C1-18 alkyl, C3-7 cycloalkyl, haloalkyl, AR' (A = bond or C1-6 (un)satd. aliph. chain, R' = (substituted) Ph or naphthyl, (substituted) heteroaryl of 5-7 atoms contg. 1-3 heteroatoms (N, O, or S)); R1 = H, lower alkyl; R2 = H, halo] are prepd. Thus, sulfonylation of .alpha.-amino deriv. (S)-II (prepn. given) with MeSO2Cl in THF with added K2CO3 afforded (S)-I (R1 = R2 = H, R = Me). Compds. I are useful as analgesics. Thus, compd. (S)-I (R1 = 3-Me, R2 = H, R = Me) was effective in inhibition of the torsion and stretching movement induced by phenylbenzoquinone in mice (ID50 = 2.8 mg kg-1). Pharmaceutical formulations of compds. I are claimed.

> d 1-2 fbib abs hitstr

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS
AN 1999:736655 CAPLUS
DN 131:351230
TI Method for stereochemically controlled preparation of isomerically pure highly substituted azacycloalkanamines and -ols
IN Reggelin, Michael; Heinrich, Timo; Junker, Bernd; Antel, Jochen; Preuschoff, Ulf
PA Solvay Pharmaceuticals G.m.b.H., Germany
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9958500	A1	19991118	WO 1999-DE1417	19990510
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				DE 1998-19821418A	19980513
	DE 19921580	A1	19991125	DE 1999-19921580	19990510
				DE 1998-19821418A1	19980513
	AU 9950250	A1	19991129	AU 1999-50250	19990510
				DE 1998-19821418A	19980513
				WO 1999-DE1417 W	19990510
	BR 9911770	A	20010206	BR 1999-11770	19990510
				DE 1998-19821418A	19980513
				WO 1999-DE1417 W	19990510
	EP 1076646	A1	20010221	EP 1999-934470	19990510
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
				DE 1998-19821418A	19980513
				WO 1999-DE1417 W	19990510
	NO 2000005666	A	20001110	NO 2000-5666	20001110
				DE 1998-19821418A	19980513
				WO 1999-DE1417 W	19990510

OS CASREACT 131:351230; MARPAT 131:351230
GI

this appn



I



II

AB Title compds. [I; R = OH or NH2; R1 = H, alkyl, (un)substituted Ph; R2 =

H; R1R2 = [alkyl- or (un)substituted Ph-substituted] CH2; R3 = H; R4 = H, alkyl, (un)substituted phenylalkyl; R3R4 = alk(en)ylene; R7 = H; R8 = H, alkyl, Co2H, CONH2, heterocyclyl, etc.; R9 = H, alkyl, phenylalkyl, etc.; R8R9 = alkylene] were prepd. using chiral S-alkenylarylsulfoximides. Thus, (+)-(RS)-(4R)-4-isopropyl-2-(p-tolyl)-4,5-dihydro[1,2.lambda.6,3]oxathiazole 2-oxide was condensed with BrMgCH2CH:CHMe and the product O-protected to give (R)-Me2CHCH(CH2OSiMe3)N:S(O)(C6H4Me-4)CH2CH:CHMe which was cyclocondensed with N-protected MeCHCH2CH(NH2)CHO (prepn. given) to give, in 1 addnl. step, title compd. (+)-(2S, 3S,4S,5S)-II.

IT **250613-41-3P**
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(method for stereochem. controlled prepn. of isomerically pure highly substituted azacycloalkanamines and -ols)

RN 250613-41-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-hydroxy-5-[[(R)-N-[(1R)-1-(1-hydroxymethyl)-2-methylpropyl]-S-(4-methylphenyl)sulfonimidoyl]methyl]-4-methyl-2-(2-methylpropyl)-, 1,1-dimethylethyl ester, (2S,3S,4S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 11
RE
(1) Beak, P; J Org Chem 1993, V58(5), P1109 CAPLUS
(2) Ciba Geigy Ag; EP 0558443 A 1993 CAPLUS
(3) Comins, D; Heterocycles 1994, V37(2), P1121 CAPLUS
(4) Fujisawa Pharmaceutical Co; EP 0394991 A 1990 CAPLUS
(5) Meleshina, A; 1974, 23, CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS
AN 1998:745666 CAPLUS
DN 130:95445
TI Metalated 2-Alkenylsulfoximides in asymmetric synthesis: diastereoselective preparation of highly substituted pyrrolidine derivatives
AU Reggelin, Michael; Heinrich, Timo
CS Fachbereich Chemie Universitat, Frankfurt/Main, D-60439, Germany
SO Angew. Chem., Int. Ed. (1998), 37(20), 2883-2886
CODEN: ACIEF5; ISSN: 1433-7851
PB Wiley-VCH Verlag GmbH
DT Journal
LA English
GI

not prior art



AB The stereoselective synthesis of enantiomerically pure, highly substituted pyrrolidine derivs. I and II (R1 = H, Me; R2 = CH2Ph, CH2CHMe2, CH2OCMe3) starting from valine-derived alkenylsulfoximides III (p-Tol = 4-MeC6H4) and their enantiomers is described. Thus, lithiation of III, followed by transmetalation with ClTi(OCHMe2)3 and reaction with 9-fluorenylmethoxycarbonyl (Fmoc)-protected .alpha.-amino aldehydes, piperidine-promoted deprotection, cyclization, re-protection with Boc2O, and desulfuration with SmI2 in MeOH gave heterocycles I. The abs. configuration at the newly formed stereogenic centers C-3 and C-4 is controlled by the abs. configuration at sulfur, and the configuration at C-5 is a result of conformational preferences of the cyclization precursor.

IT **219321-56-9P**
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(diastereoselective prepn. of highly substituted pyrrolidine derivs. via stereoselective aldol reactions of alkenylsulfoximide titanium anions with protected amino aldehydes)

RN 219321-56-9 CAPLUS

CN 3-Pyrrolidinol, 5-[[(S)-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-S-(4-methylphenyl)sulfonimidoyl]methyl]-4-methyl-2-(2-methylpropyl)-, (2S,3R,4R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **219321-41-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(diastereoselective prepn. of highly substituted pyrrolidine derivs. via stereoselective aldol reactions of alkenylsulfoximide titanium anions with protected amino aldehydes)

RN 219321-41-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-hydroxy-5-[[(S)-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-S-(4-methylphenyl)sulfonimidoyl]methyl]-4-methyl-2-(phenylmethyl)-, 1,1-dimethylethyl ester, (2S,3R,4R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 40
RE
(3) Bax, A; J Am Chem Soc 1986, V108, P2093 CAPLUS
(5) Bridges, R; Bioorg Med Chem Lett 1993, V3, P115 CAPLUS
(6) Cheung, H; Biochim Biophys Acta 1973, V293, P451 CAPLUS
(8) Deprez, P; Tetrahedron:Asymmetry 1991, V2, P1189 CAPLUS
(9) Dess, D; J Am Chem Soc 1991, V113, P7277 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

this appn.

8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopenta[c]pyrrole-2(1H)-carboxylic acid, 3a-aminohexahydro-1-methyl-3-(phenylmethyl)-, 1,1-dimethylethyl ester, (1S,3S,3aS,6aS)- (9CI)
MF C20 H30 N2 O2

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):48

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Pyrrolidinecarboxylic acid, 3-hydroxy-5-methyl-2-(2-methylpropyl)-, 1,1-dimethylethyl ester, (2S,3R,5R)- (9CI)
MF C14 H27 N O3

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Sulfoximine, N-[(1S)-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-methylpropyl]-S-methyl-S-(4-methylphenyl)-, [S(S)]- (9CI)
MF C19 H35 N O2 S Si

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopenta[c]pyrrole-2(1H)-carboxylic acid, hexahydro-3a-hydroxy-1-methyl-3-(phenylmethyl)-, 1,1-dimethylethyl ester, (1R,3S,3aR,6aR)- (9CI)
MF C20 H29 N O3

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Sulfoximine, S-(1-cyclopenten-1-ylmethyl)-N-[(1R)-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-methylpropyl]-S-(4-methylphenyl)-, [S(R)]- (9CI)
MF C24 H41 N O2 S Si

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopenta[c]pyrrole-2(1H)-carboxylic acid, 3a-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)hexahydro-1-methyl-3-phenyl-, 1,1-dimethylethyl ester, (1R,3S,3aR,6aR)- (9CI)
MF C27 H30 N2 O4

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopenta[c]pyrrole-2(1H)-carboxylic acid, 3a-aminohexahydro-1-methyl-3-phenyl-, 1,1-dimethylethyl ester, (1R,3S,3aR,6aR)- (9CI)
MF C19 H28 N2 O2

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Sulfoximine, N-[(1R)-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-methylpropyl]-S-methyl-S-(4-methylphenyl)-, [S(S)]- (9CI)
MF C19 H35 N O2 S Si

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopenta[c]pyrrole-2(1H)-carboxylic acid, hexahydro-3a-hydroxy-1-[[(S)-N-[(1R)-1-(1-hydroxymethyl)-2-methylpropyl]-S-(4-methylphenyl)sulfonimidoyl]methyl]-3-phenyl-, 1,1-dimethylethyl ester, (1S,3S,3aR,6aR)- (9CI)
MF C31 H44 N2 O5 S

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopenta[c]pyrrole-2(1H)-carboxylic acid, hexahydro-3a-hydroxy-1-methyl-3-phenyl-, 1,1-dimethylethyl ester, (1R,3S,3aR,6aR)- (9CI)
MF C19 H27 N O3

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2.lambda.4-1,2,3-Oxathiazole, 4,5-dihydro-4-(1-methylethyl)-2-(4-methylphenyl)-, 2-oxide, (2R,4R)- (9CI)
MF C12 H17 N O2 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopenta[c]pyrrol-3a(1H)-ol, 1-[[[S-(S)]-N-[(1R)-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-methylpropyl]-S-(4-methylphenyl)sulfonimidoyl]methyl]hexahydro-3-phenyl-, (1S,3S,3aR,6aR)-(9CI)
MF C32 H50 N2 O3 S Si

Absolute stereochemistry.



548/515 548/512

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Pyrrolidinecarboxylic acid, 2-[(1,1-dimethylethoxy)methyl]-3-hydroxy-5-methyl-, 1,1-dimethylethyl ester, (2S,3S,5S)- (9CI)
MF C15 H29 N O4

Absolute stereochemistry. Rotation (+).



548/556

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Carbamic acid, [(1S)-1-formyl-3-methylbutyl]-, 9H-fluoren-9-ylmethyl ester (9CI)
MF C21 H23 N O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopenta[c]pyrrole-2(1H)-carboxylic acid, 1-[[[S(R)]-N-[(1R)-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-methylpropyl]-S-(4-methylphenyl)sulfonimidoyl]methyl]hexahydro-3a-hydroxy-3-phenyl-, 1,1-dimethylethyl ester, (1R,3S,3aS,6aS)- (9CI)
MF C37 H58 N2 O5 S Si

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Pyrrolidinecarboxylic acid, 3-hydroxy-4,5-dimethyl-2-(phenylmethyl)-, 1,1-dimethylethyl ester, (2S,3S,4S,5S)- (9CI)
MF C18 H27 N O3

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2.lambda.4-1,2,3-Oxathiazole, 4,5-dihydro-4-(1-methylethyl)-2-(4-methylphenyl)-, 2-oxide, (2R,4S)- (9CI)
MF C12 H17 N O2 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Pyrrolidinecarboxylic acid, 3-hydroxy-5-[[(R)-N-[(1R)-1-(1-hydroxymethyl)-2-methylpropyl]-S-(4-methylphenyl)sulfonimidoyl]methyl]-4-methyl-2-(2-methylpropyl)-, 1,1-dimethylethyl ester, (2S,3S,4S,5R)- (9CI)
MF C27 H46 N2 O5 S

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Pyrrolidinecarboxylic acid, 3-hydroxy-5-methyl-2-(phenylmethyl)-, 1,1-dimethylethyl ester, (2S,3S,5S)- (9CI)
MF C17 H25 N O3

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzeneethanol, .beta.-amino-, (.beta.S)- (9CI)
MF C8 H11 N O
CI COM

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Sulfoximine, S-2-butenyl-N-[(1R)-1-(1-hydroxymethyl)-2-methylpropyl]-S-(4-methylphenyl)-, [S(R)]- (9CI)
MF C16 H25 N O2 S

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Pyrrolidinecarboxylic acid, 3-hydroxy-4,5-dimethyl-2-(2-methylpropyl)-, 1,1-dimethylethyl ester, (2S,3R,4R,5R)- (9CI)
MF C15 H29 N O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopentanone (8CI, 9CI)
MF C5 H8 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2H-Cyclopenta[c]pyridine-2-carboxylic acid, octahydro-4a-hydroxy-1-methyl-, 1,1-dimethylethyl ester, (1R,4aS,7aR)- (9CI)
MF C14 H25 N O3

Absolute stereochemistry. Rotation (-).



546/183

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Pyrrolidinecarboxylic acid, 2-[(1,1-dimethylethoxy)methyl]-3-hydroxy-5-methyl-, 1,1-dimethylethyl ester, (2S,3R,5R)- (9CI)
MF C15 H29 N O4

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN L-Leucine (9CI)
MF C6 H13 N O2
CI COM

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopenta[c]pyrrol-3a(1H)-ol, hexahydro-1-methyl-3-(phenylmethyl)-, (1R,3S,3aR,6aR)- (9CI)
MF C15 H21 N O

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Pyrrolidinecarboxylic acid, 3-hydroxy-5-methyl-2-(phenylmethyl)-, 1,1-dimethylethyl ester, (2S,3R,5R)- (9CI)
MF C17 H25 N O3

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Carbamic acid, [(1S)-2-oxo-1-phenylethyl]-, 9H-fluoren-9-ylmethyl ester (9CI)
MF C23 H19 N O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Pyrrolidinecarboxylic acid, 2-[(1,1-dimethylethoxy)methyl]-3-hydroxy-4,5-dimethyl-, 1,1-dimethylethyl ester, (2S,3S,4S,5S)- (9CI)
MF C16 H31 N O4

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Sulfoximine, S-(1-cyclopenten-1-ylmethyl)-N-[(1R)-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-methylpropyl]-S-(4-methylphenyl)-, [S(S)]- (9CI)
MF C24 H41 N O2 S Si

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Isoindole-1,3(2H)-dione, 2-[(1R,3S,3aR,6aR)-hexahydro-1-methyl-3-phenylcyclopenta[c]pyrrol-3a(1H)-yl]- (9CI)
MF C22 H22 N2 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopenta[c]pyrrol-3a(1H)-ol, hexahydro-1-methyl-3-phenyl-, (1R,3S,3aR,6aR)- (9CI)
MF C14 H19 N O

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Sulfoximine, N-[(1R)-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-methylpropyl]-S-methyl-S-(4-methylphenyl)-, [S(R)]- (9CI)
MF C19 H35 N O2 S Si

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopenta[c]pyrrole-2(1H)-carboxylic acid, 1-[[[S-(S)]-N-[(1R)-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-methylpropyl]-S-(4-methylphenyl)sulfonimidoyl]methyl]hexahydro-3a-hydroxy-3-phenyl-, 1,1-dimethylethyl ester, (1S,3S,3aR,6aR)- (9CI)
MF C37 H58 N2 O5 S Si

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopenta[c]pyrrole-2(1H)-carboxylic acid, hexahydro-3a-hydroxy-1-methyl-3-phenyl-, 1,1-dimethylethyl ester, (1S,3S,3aS,6aS)- (9CI)
MF C19 H27 N O3

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2.lambda.4-1,2,3-Oxathiazole, 4,5-dihydro-4-(1-methylethyl)-2-(4-methylphenyl)-, 2-oxide, (2S,4R)- (9CI)
MF C12 H17 N O2 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopenta[c]pyrrole-2(1H)-carboxylic acid, hexahydro-3a-hydroxy-1-[[(R)-N-[(1R)-1-(1-hydroxymethyl)-2-methylpropyl]-S-(4-methylphenyl)sulfonimidoyl]methyl]-3-phenyl-, 1,1-dimethylethyl ester, (1R,3S,3aS,6aS)- (9CI)
MF C31 H44 N2 O5 S

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Pyrrolidinecarboxylic acid, 3-hydroxy-4,5-dimethyl-2-(2-methylpropyl)-, 1,1-dimethylethyl ester, (2S,3S,4S,5S)- (9CI)
MF C15 H29 N O3

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2.lambda.4-1,2,3-Oxathiazole, 4,5-dihydro-4-(1-methylethyl)-2-(4-methylphenyl)-, 2-oxide, (2S,4S)- (9CI)
MF C12 H17 N O2 S

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cyclopenta[c]pyrrol-3a(1H)-ol, 1-[[[S(R)]-N-[(1R)-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-methylpropyl]-S-(4-methylphenyl)sulfonimidoyl]methyl]hexahydro-3-phenyl-, (1R,3S,3aS,6aS)-(9CI)
MF C32 H50 N2 O3 S Si

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Pyrrolidinecarboxylic acid, 3-hydroxy-5-methyl-2-(2-methylpropyl)-, 1,1-dimethylethyl ester, (2S,3S,5S)- (9CI)
MF C14 H27 N O3

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Carbamic acid, [(1S)-1-(hydroxymethyl)-3-methylbutyl]-, 9H-fluoren-9-ylmethyl ester (9CI)
MF C21 H25 N O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Sulfoximine, S-2-butenyl-S-(4-methylphenyl)-N-[(1R)-2-methyl-1-[[(trimethylsilyl)oxy]methyl]propyl]-, [S(R)]- (9CI)
MF C19 H33 N O2 S Si

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Pyrrolidinecarboxylic acid, 2-[(1,1-dimethylethoxy)methyl]-3-hydroxy-4,5-dimethyl-, 1,1-dimethylethyl ester, (2S,3R,4R,5R)- (9CI)
MF C16 H31 N O4

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2-Butene, 1-bromo- (6CI, 7CI, 8CI, 9CI)
MF C4 H7 Br
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 2(1H)-Isoquinolinecarboxylic acid, octahydro-4a-hydroxy-1-methyl-, 1,1-dimethylethyl ester, (1R,4aS,8aR)- (9CI)
MF C15 H27 N O3

Absolute stereochemistry. Rotation (-).



54b
1/47

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Pyrrolidinecarboxylic acid, 3-hydroxy-4,5-dimethyl-2-(phenylmethyl)-, 1,1-dimethylethyl ester, (2S,3R,4R,5R)- (9CI)
MF C18 H27 N O3

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 49 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1H-Isoindole-1,3(2H)-dione (9CI)
MF C8 H5 N O2
CI COM



L10 ANSWER 1 OF 37 COPYRIGHT 2002 BEILSTEIN CDS MDLI

Beilstein Reg. No. (BRN): 8180518 Beilstein
Molecular Formula (MF): C30 H44 N2 O5 S
Beilstein Reference (SO): 6-21
General Comments (NTE): Stereo compound
Rltd. Stereoisomers (RSI): 8180517
Formula Weight (FW): 544.75
Lawson Number (LN): 25073; 5224; 3151; 1762; 318



Preparation:
PRE
Start: BRN=8178275 C25H36N2O3S, BRN=1911173 tert-butyl carbonic anhydride
Reag: NaHCO3
Solv: dioxane, H2O
Reference(s):
1. Reggelin, Michael; Heinrich, Timo, Angew.Chem.Int.Ed.Engl., 37 <1998> 20, 2883-2886, LA: EN, CODEN: ACIEAY
Angew.Chem., 110 <1998>, 3005-3008, LA: EN, CODEN: ANCEAD